Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $8.99M fell 28.4% year over year, behind the -2.4% change in trailing-twelve-month research & development. Sequentially, it fell 35.5% from the prior quarter. Over 3 fiscal years it compounded at -26.2% a year.

Context

  • Research & development amounted to 11.9% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -28.4% toward the trailing-twelve-month pace of -2.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.99M-35.5% QoQ
Last fiscal yearDec 2025
$47.85M+3.5% YoY
LTMMar 2026
$44.28M-2.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.4%——
1 year+3.5%——
3-year CAGR-26.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
47.85M USD
Year-over-year change
+3.5%
4-year CAGR
-18.0%

Research & Development vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.4% is the 6th highest of 10, against a peer median of +12.8%.
  • Research & development amounts to 10.6% of revenue for ESPR, versus a peer median of 31.9%.
ESPR Competitors
Research & Development for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$2.7T USD+25130615.4%-33.8%2884018.5%
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M USD+12.8%-2.0%260.4%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$176.31M USD+40.8%+24.2%—
ABSIAbsci CorporationLTM Mar 2026$84.33M USD+24.0%+11.4%4593.1%
OFIXOrthofix Medical Inc.LTM Mar 2026$61.4M USD-16.9%+5.2%7.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$49.1M USD-30.6%-34.1%7.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$44.28M USD-2.4%-26.2%10.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$37.44M USD+64.5%+11.3%—
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.04M USD-18.6%-0.6%31.9%
SNDLSNDL Inc.LTM Mar 2026CA$393K CAD-3.9%-41.5%0.0%
Peer median (excluding ESPR) —+12.8%-0.6%31.9%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.